Why We Invested in Dioseve

Why Dioseve, Why Japan

Reproductive biology has emerged as an important frontier in hard tech, with the potential to reshape infertility. Dioseve is building at that intersection, which is a big reason we chose Dioseve as Pangaea’s first startup investment in Japan. We have been laying the groundwork to support more hard tech founders in the country, and Dioseve is the first example of that strategy in action.

Dioseve is co-founded and led by CEO Kazuma Kishida, who brings a mix of patient‑level empathy and execution experience from investment banking and company building. He has shown a clear grasp of capital raising, partnership development, and navigating different regulatory environments, which will matter as Dioseve scales beyond its first market.

A Clear Need in Fertility Care

Fertility care is a large and growing market, but it remains difficult, expensive, and often physically demanding for patients. Global fertility treatments already exceed $36 billion, while IVF success rates remain relatively low and existing in vitro maturation approaches are still underused because of inconsistent efficacy.

Too often, patients face multiple cycles, heavy hormone regimens, repeated clinic visits, and a process that asks a great deal without offering enough certainty in return. That combination makes the infertility journey more painful than it needs to be and creates an opening for products that can improve outcomes while making treatment less burdensome.

Dioseve’s first product, DIOS-101, is designed to address a meaningful part of that problem. It uses engineered granulosa‑like cells derived from iPS cells to create an ovarian‑like microenvironment in vitro, supporting the maturation of immature oocytes during IVF. In practical terms, the approach is intended to reduce hormone exposure, cut the number of clinic visits, lower overall treatment cost, and improve how fertility treatment works for both patients and clinics.

Deep Science, Practical Product

What stood out to us was not only the clinical logic of the product, but the depth of the scientific foundation behind it. Research co‑authored by Dioseve founder Dr. Nobuhiko Hamazaki identified a set of transcription factors sufficient to trigger oocyte growth and showed that pluripotent stem cells could be converted into oocyte‑like cells competent for fertilization and early cleavage.

Earlier work from the broader scientific lineage around the company demonstrated that functional mouse oocytes could be generated from pluripotent stem cells in vitro, yielding live offspring and effectively reconstituting the female germline cycle in a dish. Together, these studies provide depth for a company working in reproductive biology, especially one already advancing a product with near term clinical relevance.

In a field where scientific credibility matters enormously, Dioseve’s approach is essential: a frontier platform with genuine technical depth, paired with a first product that can reach the market sooner and begin to create value by integrating into clinical workflow.

We were also drawn to the discipline of the company’s initial commercial strategy. DIOS-101 is not framed as a distant, all-or-nothing bet on future in vitro gametogenesis. It is a nearer-term product aimed at improving an existing fertility workflow, with the potential to reduce burden for patients and create a differentiated offering for clinics in an ever-demanding market.

What We See Going Forward

More broadly, Dioseve reflects something important about where hard tech is headed. Some of the most compelling companies in biology will not be built around software abstractions or incremental service models. They will come from teams that can take deep advances in cell biology, developmental biology, and engineering and turn them into usable systems with clear clinical and commercial relevance.

That is what we see in Dioseve. A company with the potential to make fertility treatment less burdensome in the near term, while building capabilities that could transform what reproductive medicine looks like over time.